BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/22/2020 3:17:13 AM | Browse: 732 | Download: 1541
 |
Received |
|
2020-05-27 23:58 |
|
Peer-Review Started |
|
2020-05-27 23:59 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-06-13 04:13 |
|
Revised |
|
2020-08-11 10:37 |
|
Second Decision |
|
2020-08-21 12:27 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-08-21 21:04 |
|
Articles in Press |
|
2020-08-21 21:04 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-08-26 13:37 |
|
Typeset the Manuscript |
|
2020-09-16 13:59 |
|
Publish the Manuscript Online |
|
2020-09-22 03:17 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy vs combination chemotherapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Sung Yong Han, Dong Uk Kim, Young Mi Seol, Suk Kim, Nam Kyung Lee, Seung Baek Hong and Hyung-Il Seo |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIT) |
2018R1C1B5086234 |
|
| Corresponding Author |
Young Mi Seol, MD, PhD, Assistant Professor, Department of Internal Medicine and Biomedical Research Institute, Division of Hematology-Oncology, Pusan National University Hospital, Gudeok ro 179, seo-gu, Busan 49241, South Korea. seol2100@hanmail.net |
| Key Words |
Combination chemotherapy; Gemcitabine;; Pancreatic cancer; Elderly; Ductal carcinoma; Adverse drug event |
| Core Tip |
Combination therapy (gemcitabine plus nab-paclitaxel and FOLFIRINOX) is known to be more effective than gemcitabine monotherapy in pancreatic cancer patients over 65 years of age. However, the effect in the very elderly (age 75 and over) is not well known. Our retrospective study aims to compare the efficacies of gemcitabine mono versus combination therapy in very elderly pancreatic cancer patients. Our data showed that in elderly patients, combination therapy was more efficient compared to gemcitabine monotherapy. However, gemcitabine monotherapy may be a better option for managing metastatic pancreatic cancer in very elderly patients compared to combination therapy. |
| Publish Date |
2020-09-22 03:17 |
| Citation |
Han SY, Kim DU, Seol YM, Kim S, Lee NK, Hong SB, Seo HI. First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy vs combination chemotherapy. World J Clin Cases 2020; 8(18): 4022-4033 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i18/4022.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i18.4022 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
